SGS Awards FSSC 22000 V6 Certification To Dharampal Satyapal Limited
Gurugram (Haryana) [India], June 13: SGS is proud to announce the successful certification of FSSC 22000 V6, a globally recognized, GFSI-benchmarked food safety standard to the manufacturing unit of Dharampal Satyapal Limited located at Rai, Sonipat. DS Group is a prominent Indian multi-business conglomerate with a strong presence in the food & beverage, dairy, hospitality and mouth freshener sectors.
The certification of FSSC V6 of manufacturing unit located at Rai, Sonipat was given in person at DS Headquarters, Noida, following a rigorous audit against FSSC 22000's comprehensive framework, which integrates ISO 22000, relevant Pre-Requisite Programs (PRPs) and additional FSSC-specific requirements. As an ISO-based scheme, the FSSC 22000 v6 certification enables seamless integration with other management systems, streamlining audits and strengthening food safety governance. This achievement reinforces DS Group's commitment to excellence and positions it for expanded market access among global brands and retailers.
"Achieving FSSC 22000 Version6 certification from SGS is a significant milestone for DS Group. It not only validates our robust food safety management systems but also enhances our ability to meet the evolving demands of global brands and retailers, further strengthening consumer trust in our products," said Divya Jain, General Manager - Food Safety Management & Quality, Dharampal Satyapal Limited, Noida.
Speaking about this certification, Sub-Regional Director - Business Assurance for SGS in India, Nilesh Jadhav said, "As the world's leading provider of FSSC 22000 certification, SGS remains at the forefront of advancing global food safety standards. Our mission is to drive continuous improvement across the food supply chain by supporting organizations in meeting and exceeding rigorous regulatory and quality benchmarks. We are proud to have partnered with DS Group in their successful transition to FSSC 22000 Version 6, a milestone that clearly demonstrates their commitment to operational excellence, robust risk management and alignment with the highest international standards."
To know more about SGS certification services for FSSC22000 V6 - click here
For further information, please contact:
Mr. Arup Jana
t: +91 90 07 074 274
ABOUT DS GROUP
The Dharampal Satyapal Group (DS Group) is a leading Indian multi-business conglomerate with a strong presence in both domestic and international markets. Founded in 1929, the Group has evolved from its origins in perfumery and tobacco into a diversified enterprise encompassing mouth fresheners, food and beverages, confectionery, hospitality, dairy, luxury retail, restaurants & cafes, agri business and other investments. Headquartered in Noida, Uttar Pradesh, DS Group is recognized among India's top 15 FMCG companies, having surpassed a turnover of ₹10,000 crore in FY 2024-25.
ABOUT SGS
SGS is the world's leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of 99,500 dedicated professionals. With over 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability.
Our brand promise - when you need to be sure - underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and trusted specialized brands, including Brightsight, Bluesign, Maine Pointe and Nutrasource.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
28 minutes ago
- Business Standard
Brigade Hotels signs agreement to build 6 new Marriott hotels by FY30
Bengaluru-based Brigade Hotel Ventures (BHV), which recently listed on the bourses, on Wednesday signed a multi-deal agreement with global hotel chain Marriott International to develop six hotels for the company. Coming up in four key southern cities — Chennai, Bengaluru, Thiruvananthapuram and Kochi — the move will add about 940 keys to BHV's portfolio in the country, taking it to 3,300 keys. The new hotels will be classified under the Fairfield by Marriott, JW Marriott, Courtyard by Marriott and The Ritz-Carlton brands. 'With this signing, Brigade reinforces its nearly 15-year partnership with Marriott, further strengthening a successful relationship and bringing the total to eight hotels with Marriott, totalling 1,388 keys,' the company stated in a release. While the Courtyard by Marriott offering at Chennai World Trade Center with 45 keys is expected to open in financial year 2027 (FY27), the Fairfield by Marriott Bengaluru International Airport (224 keys) and Fairfield by Marriott Bengaluru Brigade Valencia (151 keys) are set to open in FY28. Additionally, the JW Marriott at OMR Chennai with 250 keys, the 70-key all-villa Ritz-Carlton Vaikom Island in Kerala, and the mixed-use Thiruvananthapuram Marriott Hotel World Trade Center with 200 keys are set to open in FY30. 'Our growth strategy focuses on being present where our guests want us to be. Today's signed agreement underscores our long-standing relationship with Brigade Hotel Ventures Limited, and leveraging the strength of our diverse brand portfolio, we are confident these new developments will meet the needs of travellers, for every trip purpose,' said Rajeev Menon, president, Asia Pacific excluding China at Marriott International. Last month, the NASDAQ-listed global hospitality major had signed an agreement with Blackstone-backed Ventive Hospitality for six new hotels — at Varanasi in Uttar Pradesh, Mundra in Gujarat, and Pune and Navi Mumbai in Maharashtra — by 2030. The American hospitality chain currently has over 155 hotels and over 29,000 rooms in more than 40 Indian cities. Earlier this year, Anthony Capuano, president and chief executive officer of Marriott International, had stated that he expects India to become its third-largest market within five years. "We will continue the momentum we enjoy in the upper, upscale, and luxury segment. We will also look at the lower end of the chain scales and create more opportunities for the value-conscious inbound international traveller and the domestic traveller," Capuano had said.
Economic Times
28 minutes ago
- Economic Times
Muthoot Finance Q1 Results: Standalone profit surges 90% to Rs 2,046 crore on strong loan growth
Indian gold loan financier Muthoot Finance reported a bigger-than-expected 90% surge in first-quarter profit on Wednesday, aided by higher loan demand as prices of the precious metal soared. ADVERTISEMENT Muthoot Finance reported a standalone profit of Rs 2,046 crore ($233.91 million) for the April-June quarter, above analysts' estimate of Rs 1,624 crore, per data compiled by LSEG. Gold prices hit multiple record highs during the quarter. This benefits gold financiers as higher prices increase the collateral value, allowing borrowers to secure larger loans for the same amount of gold. Additionally, tighter lending in the unsecured segment prompted people to shift to gold loans as an alternative source of funds, analysts said. Muthoot Finance's standalone loan assets under management rose 42% year-on-year to 1.2 trillion rupees at the end of the quarter, and interest income jumped about 53% to 55.92 billion rupees. "We are well-positioned to sustain strong growth through fiscal 2026 and beyond," Managing Director George Alexander Muthoot said in a statement. ADVERTISEMENT The company also approved equity infusion of 5 billion rupees and 2 billion rupees in its units, Muthoot Money and Muthoot Homefin, respectively. Unlock 500+ Stock Recos on App (You can now subscribe to our ETMarkets WhatsApp channel)
Mint
28 minutes ago
- Mint
Nifty Pharma index rises 1.9%: Alkem, Zydus among key gainers: Should you buy or sell pharma stocks?
Stock Market Today: The Nifty Pharma index gained 1.9% during the intraday trades on Wednesday. Alkem and Zydus stood among key gainers that led the rally The Nifty Pharma Index gained almost 2% during the intraday trade on Wednesday amid a relief rally in the Indian stock market. The Nifty Pharma Index opened at 21,803.45 levels, higher than the previous day's closing price of 21,753.50. It continued to gain further to an intraday high of 22,171.05, which meant gains of almost 2% over the previous day's close. Alkem Laboratories, Zydus Lifesciences, Laurus Labs, and Abbott India were among the key gainers that led to the rise in the Nifty Pharma pack. The US market remains critical for many Indian pharma companies. Sun Pharmaceuticals, Lupin , Dr. Reddy's, Aurobindo, Cipla, and many more derive a significant part of revenues from the US markets. Thus the danger of a 50% tax on pharmaceuticals looms, and this clearly poses a risk to the profitability of Indian pharmaceutical businesses, which rely on the US market for 30-50% of their sales. Most of these US revenues, however, come from the generic drug segment. Silver lining The silver lining remains as India remains cost-competitive compared to both the US and global peers, which should help mitigate some risks, said Ajit Banerjee, president and chief investment officer at Shriram Life Insurance. The domestic Indian pharma market (50% of the Indian pharmaceutical market) will remain unaffected by tariffs. Within the US, the impact on the generic formulations market is still uncertain, though Indian players already operate on thin margins. Tariffs could increase the drug shortages by eliminating competition in a market where pricing pressures are already intense, which could be a positive for Indian companies over the mid- to long-term, highlighted Banerjee While the recent executive order by the US Administration excludes the pharmaceutical sector from immediate tariff imposition. Any tariff action will depend on the outcome of the ongoing investigation under Section 232 of the Trade Expansion Act of 1962. Even if the India pharma tariff question is answered, Kotak Institutional expect the uncertainty to persist around whether the anticipated pharma tariffs (post the Section 232 investigation) would add to the country-specific one, definition of pharma/pharma products and then eventually how much of the tariffs are passed on and rolled back Bannerjee believes the US can either bring manufacturing back home or reduce drug prices, but not both simultaneously. Even before tariffs are finalized, the uncertainty can lead to delays in order commitments and impact sector sentiment and stock price thereby. The sector currently trades at a 1Y forward P/E of 29.7 times, above its 10-year average of 26.7x. We see tariff-induced volatility as a chance for investors to accumulate quality pharma stocks on dips, said Banerjee. Nifty Pharma has witnessed two weeks of selling pressure, especially after the recent U.S. tariff developments, as per analysts. The Pharma Index was trading near a support level on the daily time frame, where a pause in the decline was expected in the coming days, potentially leading the index towards 21,998. The outlook remains negative as long as the index fails to sustain above 22,380. On the downside, a break below 21,240 could push the index further towards the 20,380–20,140 zone, as per Kunal Kamble, Sr. Technical Research Analyst at Bonanza *
